Paper Details

  1. Home
  2. Paper Details

Riluzole and ALS therapy.

Author: HugonJ

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Amyotrophic lateral sclerosis (ALS) is a serious neurological disorder characterized by progressive muscle weakness and nerve damage. While the cause is unknown, potential factors include genetic mutations, autoimmune problems, and excessive nerve stimulation (excitotoxicity). Riluzole, a medication that reduces nerve stimulation, was studied in 77 patients with ALS. After one year, 74% of those taking riluzole were still alive compared to 58% of those taking a placebo. The increased survival was significant for all patients and those with bulbar-onset ALS (ALS that starts in the brainstem).
Paper Details　
Original Abstract of the Article :
Amyotrophic lateral sclerosis (ALS) is a severe neurological disorder clinically characterized by progressive muscle weakness, amyotrophy, fasciculations and signs of corticospinal tract deficits. The cause is unknown but several hypotheses are currently proposed. In familial forms of ALS, a mutatio...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/8873431

データ提供：米国国立医学図書館（NLM）

Riluzole and ALS Therapy

Amyotrophic lateral sclerosis (ALS), a devastating neurological disease, is like a sandstorm that slowly erodes the body's ability to move. This research explores the potential of riluzole, a drug that reduces glutamate release from nerve terminals, as a treatment for ALS. The authors discuss the various hypotheses surrounding the causes of ALS, highlighting the role of excitotoxicity and abnormal glutamate metabolism. They review a double-blind placebo-controlled study that demonstrated a significant survival benefit for patients treated with riluzole compared to those receiving placebo.

A New Oasis in the Desert of ALS: Exploring Riluzole's Potential

The study's findings offer a ray of hope for individuals battling ALS, suggesting that riluzole may slow disease progression and prolong survival. However, it's essential to note that further research is needed to optimize its use and understand its long-term effects.

Navigating the Desert of ALS: A Call for Compassion and Innovation

ALS is a challenging disease that requires ongoing research and development of new treatments. This research underscores the importance of pursuing innovative approaches to combat this debilitating condition.

Dr. Camel's Conclusion

This research highlights the potential of riluzole as a treatment for ALS, offering a ray of hope for individuals battling this devastating disease. Further research is needed to optimize its use and understand its long-term effects.

Date :
  1. Date Completed 1997-01-31
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

8873431

DOI: Digital Object Identifier

8873431

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.